Resource Networks for Protein Polymorphisms in Alzheimers Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed)

The summary for the Resource Networks for Protein Polymorphisms in Alzheimers Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Resource Networks for Protein Polymorphisms in Alzheimers Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed): This Funding Opportunity Announcement (FOA) invites U24 Cooperative Agreement applications aiming to establish several mis-folded protein polymorphisms resource networks in the area of Alzheimer's disease and its related dementias (AD/ADRD). The central goal of these resource networks is to standardize and distribute seed, oligomers, and fibrils to other investigators in order to clarify and improve the reproducibility of experiments in AD/ADRD. For the past several years, many studies have developed assays and reagents to understand the biophysical properties of various tau and A structural variants such as oligomers, protofibrils, and fibrils. As a result, many imaging, chemical, and immunological tools have been developed to detect different types of A and tau polymorphs. Establishing standards, understanding the pathological roles of these protein polymorphs, and using newly developed analytic tools to address the direct correlation between patient-to-patient variations in A and tau polymorphs are the long-term goals of the resource networks supported by this FOA.

Federal Grant Title:	Resource Networks for Protein Polymorphisms in Alzheimers Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AG-21-012
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	June 17th, 2020
Original Application Deadline:	June 17th, 2020
Posted Date:	January 27th, 2020
Creation Date:	January 27th, 2020
Archive Date:	July 23rd, 2020
Total Program Funding:	$4,500,000
Maximum Federal Grant Award:	$1,000,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	January 27th, 2020

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-21-012.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Nathan Shock Centers Coordinating Center (U24 Clinical Trial Not Allowed); • Nathan Shock Centers of Excellence in Basic Biology of Aging (P30 Clinical Trial Not Allow...; • Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (...; • Exploring Proteogenomic Approaches to Unravel the Mechanisms of Mis-Folded Protein Accumul...; • Research Training in Aging for Medical Students (T35); • Technological Enhancements and Archiving for Surveys of the Elderly: SBIR (R43/44) Initiat...; • Technological Enhancements and Archiving for Surveys of the Elderly: STTR (R41/42) Initiat...; • Technology and Aging: NIA Small Business Technology Transfer Program Initiative (STTR [R41...
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...